Several high-profile psychiatrists have criticized Sepracor for what they believe are misleading ads for the drug company's new insomnia drug, Lunesta. The psychiatrists say that consumers may be left with an unrealistic impression of just what kind of benefits the drug is likely to provide, including how fast it will take them to go to sleep and their chances for a full night's rest. This new dispute highlights the added attention drug companies are receiving for the claims they make in direct-to-consumer campaigns.
- read this report from the Boston Globe for more